Our Partnerships
As a drug-agnostic platform with GMP-validated scalability, Window’s BAM technology is being applied to advance drug candidates targeting 4 major therapeutic applications:
(i) NCE pro-drugs of frontline therapeutics with patent life extension and new/expanded indications.
(ii) Novel biologically potent drugs that without the WTx-Platform would otherwise be unusable due to poor ADME properties.
(iii) Antibody-BAM Conjugates (ABCs) that eclipse current ADC drug loading and payload capabilities for unmatched potential efficacy and safety, and;
(iv) drug combinations that enable uniform delivery to tumor sites at optimized, synergistic ratios. With this variety of potential drug development applications, Window’s BAM technologies is exceptionally well suited for partnership and collaborative therapeutics development with biopharma companies across a range of disease areas and applications.
Boston, MA, and Bethesda, MD
Window Therapeutics, Inc, announced a foundational partnership with the National Foundation for Cancer Research (NFCR) through its AIM-HI Accelerator Fund (AIM-HI) biotechnology innovation award program. As part of the collaboration, Window was awarded seed-funding to enable laboratory and operations start-up to advance the company’s lead cancer programs and novel Bottle-brush Analogue Macromolecule (BAM) platform technology. Window’s BAM platform modifies the therapeutic window of small molecule ,immune-based, and combination drug treatments to maximize efficacy specifically within disease sites.
Through this grant, NCL is working with Window by providing preclinical evaluation of WTx-Bortezomib and enable its transition to the clinic via Assay Cascade Program.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the NCL to perform preclinical efficacy and toxicity testing of nanoparticles.
In March, 2020, Window Therapeutics was awarded an Assay Cascade Grant for advancement of the WTx-Bortezomib development program. Through this grant, NCL is working with Window by providing preclinical evaluation of WTx-Bortezomib and enable its transition to the clinic via Assay Cascade Program. A robust array of physicochemical characterization, sterility and endotoxin testing, in vitro characterization, immunotoxicity, in vivo safety, pharmacokinetics, and efficacy studies are to be conducted on-site at NCL based on successful progression through each phase of evaluation. Window has received joint program approval under the Assay Cascade Grant from Directors at both the NCL and NCI.